H.B. NO. <sup>1796</sup> H.D. 1

### A BILL FOR AN ACT

RELATING TO HEALTH.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. (a) There is established within the department
2	of commerce and consumer affairs the insulin drug task force.
3	The task force shall study whether cost-sharing limits should be
4	placed on prescription insulin drugs.
5	(b) The director of commerce and consumer affairs, or the
6	director's designee, shall serve as chair of the task force.
7	The task force shall include the following members:
8	(1) The director of health, or the director's designee;
9	(2) The insurance commissioner, or the commissioner's
10	designee; and
11	(3) The chairperson of the board of trustees of the Hawaii
12	employer-union health benefits trust fund, or the
13	chairperson's designee.
14	(c) The chair of the task force shall invite
15	representatives from insurance companies, mutual benefit
16	societies, and health maintenance organizations who offer health

### HB1796 HD1 HMS 2020-0470

1

## H.B. NO. <sup>1796</sup> H.D. 1

benefit plans with prescription drug coverage to be members of
 the task force.

3 (d) The members of the task force shall serve without
4 compensation, but shall be reimbursed for necessary expenses,
5 including travel expenses, incurred for service on the task
6 force. No member of the task force shall be made subject to
7 chapter 84, Hawaii Revised Statutes, solely because of that
8 member's participation on the task force.

9 (e) The task force shall submit a report of its findings
10 and recommendations, including any proposed legislation, to the
11 legislature no later than twenty days prior to the convening of
12 the regular session of 2021.

13 (f) The insulin drug task force shall dissolve on June 30,14 2021.

15

SECTION 2. This Act shall take effect on July 1, 2050.



# H.B. NO. <sup>1796</sup> H.D. 1

Report Title: Insurance; DCCA; Insulin Drug Task Force

**Description:** Established the insulin drug task force within the DCCA to study whether cost-sharing limits should be placed on prescription insulin drugs. Effective 7/1/2050. (HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

